This printed article is located at

Corporate Profile

Established in May 2001, Cordlife Group Limited ("Cordlife", together with its subsidiaries, the "Group") is a leading consumer healthcare company dedicated to safeguarding the well-being of mother and child. The Group is listed on the Mainboard of the Singapore Exchange in 2012 and is a pioneer in private cord blood banking in Asia.

Cordlife has processing and storage facilities in six key markets across Asia, namely Singapore, Hong Kong, Malaysia, India, Indonesia and the Philippines, as well as brand presence in Myanmar and Vietnam. This makes the Group one of the leading providers for cord blood, cord lining and cord tissue banking services in the region.

The Group is one of the first private cord blood banks in Asia to release cord blood units for transplants and cellular therapy. To date, the Group has released more than 500 stem cell units for use in successful transplants and therapies.


The Group's processing and storage facilities in Hong Kong, India, the Philippines and Singapore are accredited by AABB, the organisation behind the world's gold standard for cord blood banking. Their facilities in Indonesia and Malaysia are ISO-certified.

In November 2015, Cordlife Singapore received accreditation from FACT-Netcord, another worldclass international accreditation body for cord blood banks. This makes Cordlife Singapore one of just six cord blood banks in the world to be accredited by both AABB and FACT-Netcord.

In November 2016, the Group's subsidiaries in Hong Kong and India attained accreditation from the College of American Pathologists for meeting the highest industry standards for laboratory services.


The Group introduced cord lining banking - the first complementary offering outside its core service of cord blood banking - in 2009, initially to India and thereafter to Hong Kong in 2011. Subsequently, it was offered in Singapore and the Philippines in 2013. The service is now available in all the eight Asian markets where the Group operates in.

To better meet the needs of its clients, the Group has rolled out several diagnostics services. The first, a newborn metabolic screening service sold under the brand of Metascreen, was offered in India in 2013, followed by Hong Kong, the Philippines and Indonesia in 2014. Two other diagnostics services were subsequently introduced: prenatal testing to screen for foetal chromosomal abnormalities, and paediatric eye-screening service for early detection of eye problems in children.

Please read our General Disclaimer & Warning carefully.
Use of this Website constitutes acceptance of the Terms of Website Use.
Copyright © 2018. All Rights Reserved.